Rigel Pharmaceuticals | RIGL - Interest Expense On Debt


Rigel Pharmaceuticals reported $2.06M in Interest Expense on Debt for its fiscal quarter ending in September of 2024.





Interest Expense On Debt Change Date
Agenus USD 16.02M 2.85M Dec/2025
Amgen USD 657M 4M Mar/2026
Anika Therapeutics 179.39M 556.84M Mar/2026
Arrowhead Research USD 22.5M 811K Dec/2025
AstraZeneca USD 484M 181M Dec/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Bristol-Myers Squibb USD 411M 21M Mar/2026
Daiichi Sankyo JPY 2.16B 1.33B Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Halozyme Therapeutics USD 4.91M 615K Dec/2025
Heron Therapeutics USD 600K 100K Dec/2024
Intrexon USD 2K 5K Jun/2024
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
Ligand Pharmaceuticals USD 910K 243K Sep/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pfizer USD 711M 59M Dec/2025
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Veracyte USD 2K 1000 Dec/2023